Hyloris Developmentsen Sa
Research Hyloris Developmentsen Sa (HYL) on Bullrun: market cap EUR 128.80M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHYL
- ExchangeBR
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 128.80M
- Financial periodFY2025
- RevenueEUR 7.21M
- Revenue growth-14.8%
- Net income-EUR 6.33M
- Free cash flow-EUR 6.99M
- Gross margin94.7%
Valuation Snapshot
latest market cap is EUR 128.80M.
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias;
Frequently asked questions
What is Hyloris Developmentsen Sa's market cap?
Hyloris Developmentsen Sa's market capitalization is EUR 128.80M.
What does Hyloris Developmentsen Sa do?
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain;